Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Breast Neoplasms 104Neoplasms 13Neoplasm Metastasis 8Sarcoma 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Leukemia, Myeloid, Acute 5Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Lung Neoplasms 4Liposarcoma 4Multiple Myeloma 3Head and Neck Neoplasms 3Glioblastoma 3Endometrial Neoplasms 3Colonic Neoplasms 3Breast Diseases 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Neoplasm, Residual 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Inflammation 2Estrogen Receptor-positive Breast Cancer 2Esophageal Squamous Cell Carcinoma 2

Interventions

palbociclib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × KRAS Mutant Non-Small Cell Lung Cancer × palbociclib × Clear all
NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
60 enrolled
Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡